Ironwood Pharmaceuticals Inc
$ 3.31
-2.65%
05 Jun - close price
- Market Cap 544,870,000 USD
- Current Price $ 3.31
- High / Low $ 3.47 / 3.31
- Stock P/E 5.34
- Book Value -1.32
- EPS 0.62
- Next Earning Report 2026-08-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.33 %
- ROE -5.75 %
- 52 Week High 5.78
- 52 Week Low 0.58
About
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. The company is headquartered in Boston, Massachusetts.
Analyst Target Price
$6.10
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-07 | 2026-02-25 | 2025-11-10 | 2025-08-07 | 2025-05-07 | 2025-02-27 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-02-15 | 2023-11-09 | 2023-08-08 |
| Reported EPS | 0.24 | -0.01 | 0.23 | 0.14 | -0.14 | 0.02 | 0.02 | -0.0054 | -0.02 | -0.01 | 0.12 | -6.71 |
| Estimated EPS | 0.24 | 0.0168 | 0.12 | 0.02 | -0.03 | 0.0775 | 0.1 | 0.14 | 0.15 | 0.2 | 0.16 | 0.25 |
| Surprise | 0 | -0.0268 | 0.11 | 0.12 | -0.11 | -0.0575 | -0.08 | -0.1454 | -0.17 | -0.21 | -0.04 | -6.96 |
| Surprise Percentage | 0% | -159.5238% | 91.6667% | 600% | -366.6667% | -74.1935% | -80% | -103.8571% | -113.3333% | -105% | -25% | -2784% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-06 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 0.28 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: IRWD
2026-05-21 20:39:04
Ironwood Pharmaceuticals (IRWD) has amended a prior report to detail the compensation for Ronald Silver in his new role as interim chief financial officer. He will receive a monthly interim assignment fee of $12,250 and was granted 25,000 restricted stock units (RSUs) on May 19, 2026, which will vest over two years. This compensation structure aims to align his pay with the company's share performance during his interim role.
2026-05-21 20:12:53
Ronald Silver, PFO & PAO of Ironwood Pharmaceuticals Inc. (IRWD), has been granted 25,000 shares of restricted common stock as equity compensation. This award, valued at $0.00 per share, vests in two equal installments on each approximate anniversary of the grant date. Following this transaction, Silver directly holds a total of 441,570 shares of the company's common stock, demonstrating a significant equity stake.
2026-05-15 15:39:16
Armistice Capital, LLC and Steven Boyd have reported beneficial ownership of 15,028,000 shares of Ironwood Pharmaceuticals (NASDAQ: IRWD) Class A common stock, representing 9.22% of the class, as detailed in an Amendment No. 6 to a Schedule 13G filing. Armistice Capital acts as the investment manager for Armistice Capital Master Fund Ltd., which directly holds the shares, and exercises shared voting and dispositive power. The Master Fund explicitly disclaims beneficial ownership through its Investment Management Agreement, as it lacks the ability to vote or dispose of these securities.
2026-05-15 04:39:16
This article provides recent news and financial updates for Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), including its stock performance. It compiles various news headlines from May to July 2021, covering topics like investor update calls, clinical trial results, business agreements, and quarterly earnings reports. The news also highlights broader biotech sector developments that impact IRWD.
2026-05-14 21:10:21
Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation have reported a 4.90% beneficial stake in Ironwood Pharmaceuticals Inc. This stake amounts to 8,061,073 shares of Class A common stock, with both entities holding sole voting and sole dispositive power. The disclosure was made via an Amendment No. 1 to a Schedule 13G/A SEC filing.
2026-05-14 19:10:21
This page provides recent news and press releases for Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), highlighting financial results, conference participation, and updates on their therapies and pipeline. Key announcements include strong quarterly results, maintenance of financial guidance, and developments in treatments for short bowel syndrome.
